Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B
| Autor: | M. Goutsou, Kathleen J. Propert, S. Difino, M. C. Perry, M. R. Green, C. R. Modeas, D. A. Van Echo, E. D. Mitchell, Sharon D Luikart, J. O'Donnell |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Gastroenterology Drug Administration Schedule Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Carcinoma Small Cell Lung cancer Etoposide Aged Chemotherapy Leukopenia Performance status business.industry Cancer Middle Aged medicine.disease Survival Analysis Surgery Regimen Oncology chemistry Female medicine.symptom business medicine.drug |
| Zdroj: | American journal of clinical oncology. 16(2) |
| ISSN: | 0277-3732 |
| Popis: | Previously untreated extensive small-cell lung cancer (SCLC) patients with performance status 0-2 were treated with etoposide 200 mg/m2/day on days 1-3 and carboplatin doses of 50, 100, or 125 mg/m2/day on days 1-3 in a Phase I format. Among the ten eligible patients treated with 125 mg/m2/day of carboplatin, grade 3 or 4 infection occurred in six patients, grade 4 thrombocytopenia in four patients, and there was one death with myelosuppression. Thus, this dose was considered the maximum tolerated dose (MTD), and a Phase II trial was then conducted utilizing this treatment program. In the Phase II trials, 81% of the 48 eligible patients had grade 3 or 4 leukopenia, 76% had grade 3 or 4 thrombocytopenia, and 55% had grade 3 or 4 anemia. There were three (6%) toxic deaths from myelosuppression. The objective response rate was 63% (17% complete responders) with a median response duration of 6.2 months for complete responders and 6.4 months for partial responders. Median survival was 12 months. The MTD defined by this Phase I trial represents a 67-100% increase in etoposide and a 25% increase in carboplatin compared to prior studies. Cancer and Leukemia Group B (CALGB) plans to study further dose intensification of this regimen with colony-stimulating factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|